Financings Routine −

ZYUS Life Sciences Corporation Announces Closing of First Tranche of Secured Loan Financing and Provides an Update on its Annual Filings

ZYUS Life Sciences Struggles with Regulatory Compliance Amidst Liquidity Crunch

By The Northwire Desk — AI Analysis May 20, 2026 · 22:30 ZYUS · 0.495 ZYUS Life Sciences Corporation

Executive Summary

ZYUS Life Sciences Corporation closed the first tranche of a secured loan financing, raising CAD$180,000 toward a total facility of up to CAD$2,000,000.
The company provided an update regarding delays in filing its annual audited financial statements for the fiscal year ended December 31, 2025.
Delays are attributed to complex accounting and audit procedures with auditor KPMG LLP.
The Company expects to complete required annual filings on or before the week of May 31, 2026.
The failure-to-file cease trade order (FFCTO) issued on May 6, 2026, remains in effect until filings are completed.
Insider participation contributed CAD$100,000 to this first tranche of the loan.
Interest rate is 12% per annum, payable on maturity with a maturity date of November 19, 2026.

Material Impact

The most recent news confirms the persistence of the regulatory breach announced in late April (FFCTO remains active). This prevents normal equity trading and raises significant liquidity risk for shareholders.
While the loan closing provides immediate working capital ($180k), it is a small fraction of the previously targeted $7M private placement which was cancelled, indicating difficulty accessing broader capital markets due to the regulatory status.
The 12% interest rate on secured debt increases financial burden and cash burn for a pre-revenue clinical-stage company.
Insider participation ($100k) signals management confidence but does not offset the systemic risk of the FFCTO or the high cost of capital.
Patent issuance in May (Routine - Positive) is overshadowed by the inability to trade shares due to the cease trade order, limiting investor access and liquidity.
The news is consistent with previous expectations regarding filing delays; it does not introduce a new catastrophic variable but reinforces the ongoing compliance risk that has already depressed the stock price.

ZYUS · Price

Company Overview

Company: ZYUS Life Sciences Corporation (TSXV: ZYUS).
Flagship Project: Trichomylin® softgel capsules, a novel non-opioid drug candidate for pain management.
Clinical Stage: Phase 2a UTOPIA-1 trial evaluating efficacy in cancer-related pain; Last Patient Last Visit completed April 16, 2026.
Pipeline: Second drug candidate targeting neuropathic pain (diabetic/cancer) supported by recent US Patent No. 12,616,704 for Cannabichromene (CBC) formulation.
Technology: Non-intoxicating approach to pain management using CBC monotherapy or within Trichomylin® capsules.

More from ZYUS Life Sciences Corporation